National Health (Originator Brand) Amendment Determination 2020 (No. 4) (PB 74 of 2020) (Cth)

PB 74 of 2020

National Health (Originator Brand) Amendment Determination 2020 (No. 4)

National Health Act 1953

I, NIKOLAI TSYGANOV, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB(6B) of the National Health Act 1953.

Dated     30 July 2020

NIKOLAI TSYGANOV

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

1. Name of Determination

(1)     This Determination is the National Health (Originator Brand) Amendment Determination 2020 (No. 4).

(2)     This Determination may also be cited as PB 74 of 2020.

1. Commencement

This Determination commences on 1 August 2020.

1. Amendments to PB 100 of 2015

Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).

Schedule 1     Amendments

(section 3)

[1]                   Schedule 1, (after table item 134)

Insert:

134A Levodopa with carbidopa and entacapone Stalevo 50/12.5/200mg Stalevo 75/18.75/200mg Stalevo 100/25/200mg Stalevo 125/31.25/200mg Stalevo 150/37.5/200mg Stalevo 200/50/200mg

[2]                   Schedule 1, (after table item 138)

Insert:

138A Lurasidone Latuda

[3]                   Schedule 1, (after table item 163)

Insert:

163A Nitrofurantoin Macrodantin

[4]                   Schedule 1, (table item 207)

Repeal the items:

207 Salbutamol Ventolin Rotacaps Ventolin CFC‑free Ventolin Nebules

Substitute:

207 Salbutamol Ventolin Rotacaps Ventolin CFC‑free Ventolin Ventolin Nebules